Evidence map›Paper›PMID 33479802›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021

Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis.

Adham Fani Maleki, Giulia Cisbani, Nataly Laflamme, Paul Prefontaine, Marie-Michele Plante, Joanie Baillargeon, Manu Rangachari, Jean Gosselin, Serge Rivest

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Monocyte regulation by gut microbial signals.Trends in microbiology · 2023
    Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Adham Fani MalekiNeuroscience Laboratory, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Quebec City, QC, G1V 4G2, Canada.
Giulia CisbaniNeuroscience Laboratory, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Quebec City, QC, G1V 4G2, Canada.
Nataly LaflammeNeuroscience Laboratory, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Quebec City, QC, G1V 4G2, Canada.
Paul PrefontaineNeuroscience Laboratory, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Quebec City, QC, G1V 4G2, Canada.
Marie-Michele PlanteNeuroscience Laboratory, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Quebec City, QC, G1V 4G2, Canada.
Joanie BaillargeonNeuroscience Laboratory, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Quebec City, QC, G1V 4G2, Canada.
Manu RangachariNeuroscience Laboratory, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Quebec City, QC, G1V 4G2, Canada.
Jean GosselinLaboratory of Innate Immunity, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Quebec City, QC, G1V 4G2, Canada.
Serge RivestNeuroscience Laboratory, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Quebec City, QC, G1V 4G2, Canada. serge.rivest@crchudequebec.ulaval.ca.ORCID http://orcid.org/0000-0002-6082-770X
Université Laval · CA

Funding

CIHR 331652
6 · The paper itself

Abstract

The significance of monocytes has been demonstrated in multiple sclerosis (MS). One of the therapeutic challenges is developing medications that induce mild immunomodulation that is solely targeting specific monocyte subsets without affecting microglia. Muramyl dipeptide (MDP) activates the NOD2 receptor, and systemic MDP administrations convert Ly6C

Indexed as

Acetylmuramyl-Alanyl-IsoglutamineAdjuvants, ImmunologicAnimalsDisease Models, AnimalEncephalomyelitis, Autoimmune, ExperimentalFreund's AdjuvantImmunomodulating AgentsMaleMiceMice, Inbred C57BLMonocytesMultiple SclerosisMyelin-Oligodendrocyte GlycoproteinNeuroprotective AgentsNod2 Signaling Adaptor ProteinPeptide FragmentsAcetylmuramyl-Alanyl-IsoglutamineAdjuvants, ImmunologicFreund's AdjuvantImmunomodulating AgentsMyelin-Oligodendrocyte Glycoproteinmyelin oligodendrocyte glycoprotein (35-55)Neuroprotective AgentsNod2 protein, mouseNod2 Signaling Adaptor ProteinPeptide FragmentsCuprizoneEAEMicrogliaMonocytesMultiple sclerosisNOD2 receptor

Identifiers

PMID33479802
PMCPMC8423880
OpenAlexW3123816984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.